Ronovo Surgical designed the Carina Platform with a modular structure to make it simply configurable. | Supply: Ronovo Surgical
Ronovo Surgical closed its Sequence D financing spherical with a complete funding of $67 million. Shanghai-based Ronovo provides the $67 million to a Sequence C raised earlier this 12 months, bringing its whole funding to greater than $100 million in 2025. On prime of that $100 million, the corporate additionally introduced in a $46 million Sequence B final 12 months.
Johnson & Johnson’s company enterprise capital group, JJDC, led the brand new financing. With the Sequence D closing, Ronovo additionally signed a focused collaboration settlement with J&J to advance its surgical robotic commercialization efforts in China. The collaboration provides hospitals in parts of China some great benefits of the Carina modular robotic surgical procedure platform, together with complementary J&J MedTech surgical applied sciences.
Ronovo unveiled the Carina platform in February 2023 as a modular system constructed on proprietary know-how to allow configurable robotic help for laparoscopic surgical procedures throughout a number of specialties.
Carina addresses quite a few ache factors in minimally invasive surgical procedures. The firm says it offers surgeons with the flexibleness to decide on the most effective devices and probably the most superb anatomical entry. The system obtained approval from China’s Nationwide Medical Merchandise Administration (NMPA) in March 2025. This made it the primary modular surgical robotic system within the nation to acquire a first-time submitting overlaying 4 main specialties (basic surgical procedure, gynecology, urology and thoracic surgical procedure), in response to Ronovo.
In parallel with the funding, Ronovo stated it initiated international growth efforts. It at the moment has submissions underway in Europe and South America.
“We’re grateful for the profitable closing of our Sequence D spherical led by JJDC,” stated Dr. John Ma, Ronovo’s founder, chair, and CEO. “Carina — versatile, adaptable, and inexpensive — embodies our dedication to democratizing entry to surgical robotics on a worldwide scale. We’re excited concerning the strategic collaboration with Johnson & Johnson MedTech, which is able to additional speed up our business momentum in China whereas laying the inspiration for worldwide progress.”
Lilly Asia Ventures, INCE Capital, and Granite Asia additionally participated within the spherical.
Editor’s Notice: This text was syndicated from The Robotic Report’s sibling website MassDevice.
